Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis

Immunobiology

Volumn 217, Issue 11, 2012, Pages 1097-1105

  DeAngelis, Robert A ^a   Reis, Edimara S ^a   Ricklin, Daniel ^a   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Complement; Hemodialysis; Inflammation; Innate immunity; Therapeutics

Indexed keywords

C REACTIVE PROTEIN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1Q; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; ECULIZUMAB; INTERLEUKIN 6; PEPTIDOMIMETIC AGENT; PMX 53; POT 4; THROMBOPLASTIN; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; CARDIOVASCULAR DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; COMPLEMENT LECTIN PATHWAY; CYTOKINE PRODUCTION; DIALYSIS MEMBRANE; DISEASE EXACERBATION; HEMODIALYSIS; HEMOLYSIS; HUMAN; INFLAMMATION; KIDNEY FAILURE; LEUKOPENIA; MORTALITY; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PSORIASIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL RATE; THROMBOSIS;

EID: 84866045427     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.07.012     Document Type: Review

References (135)

1. Acosta J., Hettinga J., Fluckiger R., Krumrei N., Goldfine A., Angarita L., Halperin J. Molecular basis for a link between complement and the vascular complications of diabetes. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5450-5455.
2. Agalou S., Ahmed N., Babaei-Jadidi R., Dawnay A., Thornalley P.J. Profound mishandling of protein glycation degradation products in uremia and dialysis. J. Am. Soc. Nephrol. 2005, 16:1471-1485.
3. Agostoni A., Cicardi M., Bergamaschini L., Boccassini G., Tucci A. C1-inhibitor concentrate for treatment of hereditary angioedema. N. Engl. J. Med. 1980, 303:527.
4. Alcon Research, 2012. Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration (AMD). Source: ClinicalTrials.gov - NIH. http://clinicaltrials.gov/ct2/show/NCT01157065.
5. Amara U., Flierl M.A., Rittirsch D., Klos A., Chen H., Acker B., Bruckner U.B., Nilsson B., Gebhard F., Lambris J.D., Huber-Lang M. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 2010, 185:5628-5636.
6. Andersson J., Bexborn F., Klinth J., Nilsson B., Ekdahl K.N. Surface-attached PEO in the form of activated Pluronic with immobilized factor H reduces both coagulation and complement activation in a whole-blood model. J. Biomed. Mater. Res. A 2006, 76:25-34.
7. Andersson J., Ekdahl K.N., Lambris J.D., Nilsson B. Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials 2005, 26:1477-1485.
8. Andersson J., Ekdahl K.N., Larsson R., Nilsson U.R., Nilsson B. C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. J. Immunol. 2002, 168:5786-5791.
9. Andersson J., Larsson R., Richter R., Ekdahl K.N., Nilsson B. Binding of a model regulator of complement activation (RCA) to a biomaterial surface: surface-bound factor H inhibits complement activation. Biomaterials 2001, 22:2435-2443.
10. Andersson J., Sanchez J., Ekdahl K.N., Elgue G., Nilsson B., Larsson R. Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro. J. Biomed. Mater. Res. A 2003, 67:458-466.
11. Austin G.E., Mullins R.H., Morin L.G. Non-enzymic glycation of individual plasma proteins in normoglycemic and hyperglycemic patients. Clin. Chem. 1987, 33:2220-2224.
12. Besarab A., Bolton W.K., Browne J.K., Egrie J.C., Nissenson A.R., Okamoto D.M., Schwab S.J., Goodkin D.A. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 1998, 339:584-590.
13. Bologa R.M., Levine D.M., Parker T.S., Cheigh J.S., Serur D., Stenzel K.H., Rubin A.L. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am. J. Kidney Dis. 1998, 32:107-114.
14. Bray B.L. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat. Rev. Drug Discov. 2003, 2:587-593.
15. Caglar K., Peng Y., Pupim L.B., Flakoll P.J., Levenhagen D., Hakim R.M., Ikizler T.A. Inflammatory signals associated with hemodialysis. Kidney Int. 2002, 62:1408-1416.
16. Caliezi C., Wuillemin W.A., Zeerleder S., Redondo M., Eisele B., Hack C.E. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev. 2000, 52:91-112.
17. Canivet E., Lavaud S., Wong T., Guenounou M., Willemin J.C., Potron G., Chanard J. Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis. Am. J. Kidney Dis. 1994, 23:41-46.
18. Cano N.J., Fouque D., Roth H., Aparicio M., Azar R., Canaud B., Chauveau P., Combe C., Laville M., Leverve X.M., French Study Group for Nutrition in Dialysis Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J. Am. Soc. Nephrol. 2007, 18:2583-2591.
19. Cavaillon J.M., Poignet J.L., Fitting C., Delons S. Serum interleukin-6 in long-term hemodialyzed patients. Nephron 1992, 60:307-313.
20. Cavalli A., Del Vecchio L., Manzoni C., Locatelli F. Hemodialysis: yesterday, today and tomorrow. Minerva Urol. Nefrol. 2010, 62:1-12.
21. Chen H., Ricklin D., Hammel M., Garcia B.L., McWhorter W.J., Sfyroera G., Wu Y.Q., Tzekou A., Li S., Geisbrecht B.V., Woods V.L., Lambris J.D. Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17621-17626.
22. Cheng Y., Gao M. The effect of glycation of CD59 on complement-mediated cytolysis. Cell. Mol. Immunol. 2005, 2:313-317.
23. Chenoweth D.E., Cheung A.K., Henderson L.W. Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes. Kidney Int. 1983, 24:764-769.
24. Cheung A.K. Biocompatibility of hemodialysis membranes. J. Am. Soc. Nephrol. 1990, 1:150-161.
25. Cheung A.K., Parker C.J., Wilcox L., Janatova J. Activation of the alternative pathway of complement by cellulosic hemodialysis membranes. Kidney Int. 1989, 36:257-265.
26. Chi Z.L., Yoshida T., Lambris J.D., Iwata T. Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv. Exp. Med. Biol. 2010, 703:127-135.
27. Craddock P.R., Fehr J., Brigham K.L., Kronenberg R.S., Jacob H.S. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N. Engl. J. Med. 1977, 296:769-774.
28. Craddock P.R., Fehr J., Dalmasso A.P., Brighan K.L., Jacob H.S. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J. Clin. Invest. 1977, 59:879-888.
29. Cronin R.E., Reilly R.F. Unfractionated heparin for hemodialysis: still the best option. Semin. Dial. 2010, 23:510-515.
30. Davenport A. What are the anticoagulation options for intermittent hemodialysis?. Nat. Rev. Nephrol. 2011, 7:499-508.
31. Davenport A. Membrane designs and composition for hemodialysis, hemofiltration and hemodialfiltration: past, present and future. Minerva Urol. Nefrol. 2010, 62:29-40.
32. David S., Tetta C., Camussi G., Canino F., Almici C., Rizzoli V., Cambi V. Adherence of human monocytes to haemodialysis membranes. Nephrol. Dial. Transplant. 1993, 8:1223-1227.
33. Davies C.S., Harris C.L., Morgan B.P. Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects. Immunology 2005, 114:280-286.
34. De S.J., Groner A., Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus. Apher. Sci. 2003, 29:247-254.
35. Deppisch R., Schmitt V., Bommer J., Hansch G.M., Ritz E., Rauterberg E.W. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int. 1990, 37:696-706.
36. Ekdahl K.N., Lambris J.D., Elwing H., Ricklin D., Nilsson P.H., Teramura Y., Nicholls I.A., Nilsson B. Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv. Drug Deliv. Rev. 2011, 63:1042-1050.
37. Engberg A.E., Sandholm K., Bexborn F., Persson J., Nilsson B., Lindahl G., Ekdahl K.N. Inhibition of complement activation on a model biomaterial surface by streptococcal M protein-derived peptides. Biomaterials 2009, 30:2653-2659.
38. Engelberts I., Francot G.J., Leunissen K.M., Haenen B., Ceska M., van der Linden C.J., Buurman W.A. Effect of hemodialysis on peripheral blood monocyte tumor necrosis factor-alpha, interleukin-6, and interleukin-8 secretion in vitro. Nephron 1994, 66:396-403.
39. Fujimori A., Naito H., Miyazaki T. Adsorption of complement, cytokines, and proteins by different dialysis membrane materials: evaluation by confocal laser scanning fluorescence microscopy. Artif. Organs 1998, 22:1014-1017.
40. Galli F. Protein damage and inflammation in uraemia and dialysis patients. Nephrol. Dial. Transplant. 2007, 22(Suppl. 5):v20-v36.
41. Girndt M., Heisel O., Kohler H. Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study. Nephrol. Dial. Transplant. 1999, 14:676-682.
42. Grooteman M.P., Nube M.J., Daha M.R., Van L.J., van D.M., Schoorl M., Bet P.M., Van Houte A.J. Cytokine profiles during clinical high-flux dialysis: no evidence for cytokine generation by circulating monocytes. J. Am. Soc. Nephrol. 1997, 8:1745-1754.
43. Haeffner-Cavaillon N., Jahns G., Poignet J.L., Kazatchkine M.D. Induction of interleukin-1 during hemodialysis. Kidney Int. Suppl. 1993, 39:S139-S143.
44. Hair P.S., Echague C.G., Rohn R.D., Krishna N.K., Nyalwidhe J.O., Cunnion K.M. Hyperglycemic conditions inhibit C3-mediated immunologic control of Staphylococcus aureus. J. Transl. Med. 2012, 10:35.
45. Hakim R.M. Clinical implications of hemodialysis membrane biocompatibility. Kidney Int. 1993, 44:484-494.
46. Haubitz M., Schulze M., Koch K.M. Increase of C-reactive protein serum values following haemodialysis. Nephrol. Dial. Transplant. 1990, 5:500-503.
47. Haupt K., Reuter M., van den E.J., Burman J., Halbich S., Richter J., Skerka C., Zipfel P.F. The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement Factor H and C3b. PLoS Pathog. 2008, 4:e1000250.
48. Hauser A.C., Derfler K., Stockenhuber F., Janata O., Balcke P. Generation of the membrane attack complex during haemodialysis: impact of classical and alternative pathway components. Clin. Sci. (Lond) 1990, 79:471-476.
49. Herbelin A., Nguyen A.T., Zingraff J., Urena P., Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int. 1990, 37:116-125.
50. Herbelin A., Urena P., Nguyen A.T., Zingraff J., Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int. 1991, 39:954-960.
51. Hezmee M.N., Shiels I.A., Rolfe B.E., Mills P.C. Complement C5a: impact on the field of veterinary medicine. Vet. J. 2012, 192:264-271.
52. Himmelfarb J., Phinney S., Ikizler T.A., Kane J., McMonagle E., Miller G. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J. Ren. Nutr. 2007, 17:296-304.
53. Holland M.C., Morikis D., Lambris J.D. Synthetic small-molecule complement inhibitors. Curr. Opin. Investig. Drugs 2004, 5:1164-1173.
54. Hung A.M., Ellis C.D., Shintani A., Booker C., Ikizler T.A. IL-1beta receptor antagonist reduces inflammation in hemodialysis patients. J. Am. Soc. Nephrol. 2011, 22:437-442.
55. Jamison R.L., Hartigan P., Kaufman J.S., Goldfarb D.S., Warren S.R., Guarino P.D., Gaziano J.M., Veterans A.S.I. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. J. Am. Med. Assoc. 2007, 298:1163-1170.
56. Janssen B.J., Halff E.F., Lambris J.D., Gros P. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J. Biol. Chem. 2007, 282:29241-29247.
57. Jenkins H.T., Mark L., Ball G., Persson J., Lindahl G., Uhrin D., Blom A.M., Barlow P.N. Human C4b-binding protein, structural basis for interaction with streptococcal M protein, a major bacterial virulence factor. J. Biol. Chem. 2006, 281:3690-3697.
58. Kaizu Y., Kimura M., Yoneyama T., Miyaji K., Hibi I., Kumagai H. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am. J. Kidney Dis. 1998, 31:93-100.
59. Katragadda M., Magotti P., Sfyroera G., Lambris J.D. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J. Med. Chem. 2006, 49:4616-4622.
60. Kimmel P.L., Phillips T.M., Simmens S.J., Peterson R.A., Weihs K.L., Alleyne S., Cruz I., Yanovski J.A., Veis J.H. Immunologic function and survival in hemodialysis patients. Kidney Int. 1998, 54:236-244.
61. Kirschfink M., Mollnes T.E. C1-inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert Opin. Pharmacother. 2001, 2:1073-1083.
62. Klos A., Tenner A.J., Johswich K.O., Ager R.R., Reis E.S., Kohl J. The role of the anaphylatoxins in health and disease. Mol. Immunol. 2009, 46:2753-2766.
63. Köhl J. Drug evaluation: the C5a receptor antagonist PMX-53. Curr. Opin. Mol. Ther. 2006, 8:529-538.
64. Kourtzelis I., Markiewski M.M., Doumas M., Rafail S., Kambas K., Mitroulis I., Panagoutsos S., Passadakis P., Vargemezis V., Magotti P., Qu H., Mollnes T.E., Ritis K., Lambris J.D. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood 2010, 116:631-639.
65. Lambris J.D., Ricklin D., Geisbrecht B.V. Complement evasion by human pathogens. Nat. Rev. Microbiol. 2008, 6:132-142.
66. Lappegard K.T., Bergseth G., Riesenfeld J., Pharo A., Magotti P., Lambris J.D., Mollnes T.E. The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J. Biomed. Mater. Res. A 2008, 87:129-135.
67. Lappegard K.T., Fung M., Bergseth G., Riesenfeld J., Lambris J.D., Videm V., Mollnes T.E. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. Ann. Thorac. Surg. 2004, 77:932-941.
68. Lauterbach M., Horstick G., Plum N., Lotz J., Lauterbach E., Weilemann L.S., Kempski O. C1-esterase inhibitor reverses functional consequences of superior mesenteric artery ischemia/reperfusion by limiting reperfusion injury and restoring microcirculatory perfusion. Shock 2007, 27:75-83.
69. Lazar H.L., Bokesch P.M., van L.F., Fitzgerald C., Emmett C., Marsh H.C., Ryan U., OBE and the TP Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 2004, 110:II274-II279.
70. Lazar H.L., Keilani T., Fitzgerald C.A., Shapira O.M., Hunter C.T., Shemin R.J., Marsh H.C., Ryan U.S. Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference?. Circulation 2007, 116:I83-I88.
71. Lhotta K., Wurzner R., Kronenberg F., Oppermann M., Konig P. Rapid activation of the complement system by cuprophane depends on complement component C4. Kidney Int. 1998, 53:1044-1051.
72. Loirat C., Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J. Rare. Dis. 2011, 6:60.
73. Longhurst H.J., Carr S., Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin. Exp. Immunol. 2007, 147:11-17.
74. Lonnemann G., Bingel M., Koch K.M., Shaldon S., Dinarello C.A. Plasma interleukin-1 activity in humans undergoing hemodialysis with regenerated cellulosic membranes. Lymphokine Res. 1987, 6:63-70.
75. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., Ngampasutadol J., Vogel U., Granoff D.M., Ram S. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 2006, 177:501-510.
76. Magotti P., Ricklin D., Qu H., Wu Y.Q., Kaznessis Y.N., Lambris J.D. Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. J. Mol. Recognit. 2009, 22:495-505.
77. Mares J., Richtrova P., Hricinova A., Tuma Z., Moravec J., Lysak D., Matejovic M. Proteomic profiling of blood-dialyzer interactome reveals involvement of lectin complement pathway in hemodialysis-induced inflammatory response. Proteomics Clin. Appl. 2010, 4:829-838.
78. Mares J., Thongboonkerd V., Tuma Z., Moravec J., Matejovic M. Specific adsorption of some complement activation proteins to polysulfone dialysis membranes during hemodialysis. Kidney Int. 2009, 76:404-413.
79. Markiewski M.M., DeAngelis R.A., Lambris J.D. Complexity of complement activation in sepsis. J. Cell. Mol. Med. 2008, 12:2245-2254.
80. Mege J.L., Brunet P., Capo C., Dussol B., Bongrand P., Berland Y. Non-endotoxinic tumour necrosis factor-alpha-inducing factors in haemodialysis. Nephrol. Dial. Transplant. 1994, 9:1606-1610.
81. Memoli B., Postiglione L., Cianciaruso B., Bisesti V., Cimmaruta C., Marzano L., Minutolo R., Cuomo V., Guida B., Andreucci M., Rossi G. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney Int. 2000, 58:417-424.
82. Moen O., Hogasen K., Fosse E., Dregelid E., Brockmeier V., Venge P., Harboe M., Mollnes T.E. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann. Thorac. Surg. 1997, 63:105-111.
83. Mollnes T.E., Riesenfeld J., Garred P., Nordstrom E., Hogasen K., Fosse E., Gotze O., Harboe M. A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif. Organs 1995, 19:909-917.
84. Nielsen E.W., Waage C., Fure H., Brekke O.L., Sfyroera G., Lambris J.D., Mollnes T.E. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement. Mol. Immunol. 2007, 44:1819-1826.
85. Niemann M.A., Bhown A.S., Miller E.J. The principal site of glycation of human complement factor B. Biochem. J. 1991, 274(Pt 2):473-480.
86. Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. The role of complement in biomaterial-induced inflammation. Mol. Immunol. 2007, 44:82-94.
87. Nilsson B., Korsgren O., Lambris J.D., Ekdahl K.N. Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?. Trends Immunol. 2010, 31:32-38.
88. Nilsson B., Larsson R., Hong J., Elgue G., Ekdahl K.N., Sahu A., Lambris J.D. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 1998, 92:1661-1667.
89. Nilsson U.R. Deposition of C3b/iC3b leads to the concealment of antigens, immunoglobulins and bound C1q in complement-activating immune complexes. Mol. Immunol. 2001, 38:151-160.
90. NKUDIC, 2012. Kidney and Urologic Diseases Statistics for the United States. Source: National Kidney & Urologic Diseases Information Clearinghouse (NKUDIC) - A service of the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) - National Institutes of Health (NIH). http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/.
91. Oikonomopoulou K., Ricklin D., Ward P.A., Lambris J.D. Interactions between coagulation and complement - their role in inflammation. Semin. Immunopathol. 2012, 34:151-165.
92. Pensky J., Levy L.R., Lepow I.H. Partial purification of a serum inhibitor of C'1-esterase. J. Biol. Chem. 1961, 236:1674-1679.
93. Pereira B.J. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, Agadoa L. Kidney Int. 1997, 1996(50):566-570. Semin. Dial. 10, 61-62.
94. Pereira B.J., Shapiro L., King A.J., Falagas M.E., Strom J.A., Dinarello C.A. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 1994, 45:890-896.
95. Persson J., Beall B., Linse S., Lindahl G. Extreme sequence divergence but conserved ligand-binding specificity in Streptococcus pyogenes M protein. PLoS Pathog. 2006, 2:e47.
96. Pupim L.B., Himmelfarb J., McMonagle E., Shyr Y., Ikizler T.A. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int. 2004, 65:2371-2379.
97. Qu H., Magotti P., Ricklin D., Wu E.L., Kourtzelis I., Wu Y.Q., Kaznessis Y.N., Lambris J.D. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol. Immunol. 2011, 48:481-489.
98. Qu H., Ricklin D., Bai H., Chen H., Reis E.S., Maciejewski M., Tzekou A., DeAngelis R.A., Resuello R.R., Lupu F., Barlow P.N., Lambris J.D. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 2012, in press. 10.1016/j.imbio.2012.06.003.
99. Qu H., Ricklin D., Lambris J.D. Recent developments in low molecular weight complement inhibitors. Mol. Immunol. 2009, 47:185-195.
100. Rao M., Guo D., Perianayagam M.C., Tighiouart H., Jaber B.L., Pereira B.J., Balakrishnan V.S. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 2005, 45:324-333.
101. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
102. Ricklin D., Lambris J.D. Compstatin: a complement inhibitor on its way to clinical application. Adv. Exp. Med. Biol. 2008, 632:273-292.
103. Ricklin, D., Lambris, J.D., 2012. Progress and trends in complement therapeutics. Adv. Exp. Med. Biol., in press.
104. Ricklin D., Lambris J.D. Complement-targeted therapeutics. Nat. Biotechnol. 2007, 25:1265-1275.
105. Risitano A.M., Perna F., Selleri C. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3. Mini Rev. Med. Chem. 2011, 11:528-535.
106. Sahu A., Morikis D., Lambris J.D. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol. Immunol. 2003, 39:557-566.
107. Schindler R., Boenisch O., Fischer C., Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin. Nephrol. 2000, 53:452-459.
108. Schmidt S., Haase G., Csomor E., Lutticken R., Peltroche-Llacsahuanga H. Inhibitor of complement, Compstatin, prevents polymer-mediated Mac-1 up-regulation of human neutrophils independent of biomaterial type tested. J. Biomed. Mater. Res. A 2003, 66:491-499.
109. Schneider M.C., Exley R.M., Chan H., Feavers I., Kang Y.H., Sim R.B., Tang C.M. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 2006, 176:7566-7575.
110. Schneider M.C., Prosser B.E., Caesar J.J., Kugelberg E., Li S., Zhang Q., Quoraishi S., Lovett J.E., Deane J.E., Sim R.B., Roversi P., Johnson S., Tang C.M., Lea S.M. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 2009, 458:890-893.
111. Schouten W.E., Grooteman M.P., Van Houte A.J., Schoorl M., Van L.J., Nube M.J. Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrol. Dial. Transplant. 2000, 15:379-384.
112. Shao B., Pennathur S., Pagani I., Oda M.N., Witztum J.L., Oram J.F., Heinecke J.W. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J. Biol. Chem. 2010, 285:18473-18484.
113. Silasi-Mansat R., Zhu H., Popescu N.I., Peer G., Sfyroera G., Magotti P., Ivanciu L., Lupu C., Mollnes T.E., Taylor F.B., Kinasewitz G., Lambris J.D., Lupu F. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 2010, 116:1002-1010.
114. Silverstein D.M. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr. Nephrol. 2009, 24:1445-1452.
115. Soulika A.M., Khan M.M., Hattori T., Bowen F.W., Richardson B.A., Hack C.E., Sahu A., Edmunds L.H., Lambris J.D. Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clin. Immunol. 2000, 96:212-221.
116. Stenvinkel P., Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin. Dial. 2002, 15:329-337.
117. Stenvinkel P., Rodriguez-Ayala E., Massy Z.A., Qureshi A.R., Barany P., Fellstrom B., Heimburger O., Lindholm B., Alvestrand A. Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2006, 1:281-287.
118. Suki W.N., Zabaneh R., Cangiano J.L., Reed J., Fischer D., Garrett L., Ling B.N., Chasan-Taber S., Dillon M.A., Blair A.T., Burke S.K. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007, 72:1130-1137.
119. Thern A., Stenberg L., Dahlback B., Lindahl G. Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement system. J. Immunol. 1995, 154:375-386.
120. Thiara A.S., Mollnes T.E., Videm V., Andersen V.Y., Svennevig K., Kolset S.O., Fiane A.E. Biocompatibility and pathways of initial complement pathway activation with Phisio- and PMEA-coated cardiopulmonary bypass circuits during open-heart surgery. Perfusion 2011, 26:107-114.
121. Thornalley P.J. Quantitative screening of protein glycation, oxidation, and nitration adducts by LC-MS/MS: protein damage in diabetes, uremia, cirrhosis, and Alzheimer's disease. Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases 2006, 681-727. John Wiley & Sons, Inc. I. Dalle-Donne, A. Scaloni, D.A. Butterfield (Eds.).
122. Thornalley P.J., Battah S., Ahmed N., Karachalias N., Agalou S., Babaei-Jadidi R., Dawnay A. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 2003, 375:581-592.
123. Thornalley P.J., Langborg A., Minhas H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 1999, 344(Pt1):109-116.
124. Thornalley P.J., Rabbani N. Protein damage in diabetes and uremia - identifying hotspots of proteome damage where minimal modification is amplified to marked pathophysiological effect. Free Radic. Res. 2011, 45:89-100.
125. Uda S., Mizobuchi M., Akizawa T. Biocompatible characteristics of high-performance membranes. Contrib. Nephrol. 2011, 173:23-29.
126. Vlieghe P., Lisowski V., Martinez J., Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov. Today 2010, 15:40-56.
127. Wagenaar-Bos I.G., Hack C.E. Structure and function of C1-inhibitor. Immunol. Allergy Clin. North Am. 2006, 26:615-632.
128. Wanner C., Krane V., Marz W., Olschewski M., Mann J.F., Ruf G., Ritz E., German Diabetes and Dialysis Study Investigators Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005, 353:238-248.
129. Warren O.J., Smith A.J., Alexiou C., Rogers P.L., Jawad N., Vincent C., Darzi A.W., Athanasiou T. The inflammatory response to cardiopulmonary bypass: Part 1 - Mechanisms of pathogenesis. J. Cardiothorac. Vasc. Anesth. 2009, 23:223-231.
130. Wu Y.Q., Qu H., Sfyroera G., Tzekou A., Kay B.K., Nilsson B., Nilsson E.K., Ricklin D., Lambris J.D. Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J. Immunol. 2011, 186:4269-4277.
131. Yao Q., Axelsson J., Stenvinkel P., Lindholm B. Chronic systemic inflammation in dialysis patients: an update on causes and consequences. ASAIO J. 2004, 50:lii-lvii.
132. Yeun J.Y., Levine R.A., Mantadilok V., Kaysen G.A. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 2000, 35:469-476.
133. Zhang Q., Monroe M.E., Schepmoes A.A., Clauss T.R., Gritsenko M.A., Meng D., Petyuk V.A., Smith R.D., Metz T.O. Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic subjects. J. Proteome Res. 2011, 10:3076-3088.
134. Zimmermann J., Herrlinger S., Pruy A., Metzger T., Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999, 55:648-658.
135. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 2009, 9:729-740.